Abstract Objective To evaluate the clinical features, treatment outcome, and prognostic factors in patients with primary Waldeyer’s ring diffuse large B-cell lymphoma (WR-DLBCL). Methods This study included 200 patients with a confirmed diagnosis of primary WR-DLBCL admitted to our hospital from 2000 to 2013, who consisted of 50 stage I patients, 125 stage II patients, and 25 stage III-IV patients. Most patients received 4-6 cycles of CHOP or CHOP-based chemotherapy with or without involved field radiotherapy (Waldeyer′s ring+cervical lymph node region). Results The 5-year sample size was 71. The 5-year overall survival (OS), progression-free survival (PFS), and locoregional control (LRC) rates for the whole group were 78%, 72%, and 87%, respectively. In the 175 early stage patients, chemoradiotherapy resulted in significantly higher OS, PFS, and LRC than chemotherapy alone (86% vs. 70%, P=0.001;84% vs. 58%, P=0.000;97% vs. 66%, P=0.000).Univariate analysis showed that age, tumor size, stage, lactate dehydrogenase level, and International Prognostic Index were prognostic factors for OS, PFS, and LRC (P=0.000-0.036), while the prognostic factors for PFS also included Eastern Cooperative Oncology Group score and cervical nodal involvement (P=0.018). Multivariate analysis showed that age and stage were prognostic factors for OS and LRC (P=0.003-0.022), and age was the prognostic factor for PFS (P=0.000). Conclusions WR-DLBCL has distinct clinical features and favorable prognoses. For early stage patients, combined-modality therapy results in significantly higher OS, PFS, and LRC.
Xu Yonggang,Li Yexiong,Wang Weihu et al. Clinical outcome and prognosis of Waldeyer’s ring diffuse large B-cell lymphoma:an analysis of 200 patients[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 382-386.
Xu Yonggang,Li Yexiong,Wang Weihu et al. Clinical outcome and prognosis of Waldeyer’s ring diffuse large B-cell lymphoma:an analysis of 200 patients[J]. Chinese Journal of Radiation Oncology, 2015, 24(4): 382-386.
[1] 李晔雄,高远红,袁智勇,等.国际预后指数在韦氏环非霍奇金淋巴瘤的预后意义[J].中华放射肿瘤学杂志,2002,11(2):105-110. [2] Qi SN,Li YX,Wang H, et al. Diffuse large B-cell lymphoma:clinical characterization and prognosis of Waldeyer ring versus lymph node presentation[J]. Cancer,2009,115(21):4980-4989.DOI:10.1002/cncr.24557. [3] Wu RY,Li YX,Wang WH,et al. Clinical disparity and favorable prognoses for patients with Waldeyer ring extranodal nasal-type NK/T-cell lymphoma and diffuse large B-cell lymphoma[J]. Am J Clin Oncol,2014,37(1):41-46.DOI:10.1097/COC.0b013e318261084b. [4] Miller TP,Dahlberg S,Cassady JR,et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate-and high-grade non-Hodgkin′s lymphoma[J]. N Engl J Med,1998,339(1):21-6. [5] Horning SJ,Weller E,Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin′s lymphoma:Eastern Cooperative Oncology Group study 1484[J]. J Clin Oncol,2004,22(15):3032-3038. [6] Reyes F,Lepage E,Ganem G,et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma[J]. N Engl J Med,2005,352(12):1197-205. [7] Bonnet C,Fillet G,Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:a study by the Groupe d′Etude des Lymphomes de l′Adulte[J]. J Clin Oncol,2007,25(7):787-792. [8] Laskar S,Muckaden MA,Bahl G,et al. Primary non-Hodgkin’s lymphoma of the nasopharynx:prognostic factors and outcome of 113 Indian patients[J]. Leuk Lymphoma,2006,47(10):2132-2139. [9] 高远红,李晔雄,袁智勇,等.原发扁桃体非霍奇金淋巴瘤的预后因素[J].中华肿瘤杂志,2002,24(5):483-485. [10] Mohammadianpanah M,Daneshbod Y, Ramzi N,et al. Primary tonsillar lymphomas according to the new World Health Organization classification:to report 87 cases and literature review and analysis[J]. Ann Hematol,2010,89(10):993-1001. [11] Laskar S,Bahl G,Muckaden MA, et al. Primary diffuse large B-cell lymphoma of the tonsil:is a higher radiotherapy dose required[J]. Cancer,2007,110(4):816-823. [12] Mian M1,Ferreri AJ,Rossi A,et al. Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer′s ring in remission after anthracycline-containing chemotherapy[J]. Leuk Lymphoma,2013,54(1):62-68.DOI:10.3109/10428194.2012.710907. [13] Nishioka T,Tsuchiya K,Nishioka S,et al. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin′s lymphoma of the head and neck[J]. Int J Radiat Oncol Biol Phys,2004,60(3):847-852. [14] Laskar S,Mohindra P,Gupta S,et al. Non-Hodgkin lymphoma of the Waldeyer′s ring:clinicopathologic and therapeutic issues[J]. Leuk Lymphoma,2008,49(12):2263-2271.DOI:10.1080/10428190802493686. [15] López-Guillermo A,Colomo L,Jiménez M, et al. Diffuse large B-cell lymphoma:clinical and biological characterization and outcome according to the nodal or extranodal primary origin[J]. J Clin Oncol,2005,23(12):2797-2804. [16] 赵路军,李晔雄,袁智勇,等.原发于舌根非霍奇金淋巴瘤临床特点和预后[J].中华放射肿瘤学杂志,2003,12(1):21-24. [17] Harabuchi Y,Tsubota H,Ohguro S,et al. Prognostic factors and treatment outcome in non-Hodgkin′s lymphoma of Waldeyer′s ring[J]. Acta Oncol,1997,36(4):413-420. [18] Shipp MA,Harrington DP,Anderson JR,et al. A predictive model for aggressive non-Hodgkin′s lymphoma[J]. N Engl J Med,1993,329(14):987-994. [19] Phan J,Mazloom A,Medeiros LJ, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy[J]. J Clin Oncol,2010,28(27):4170-4176.DOI:10.1200/JCO.2009.27.3441. [20] Ballonoff A,Rusthoven KE,Schwer A,et al. Outcomes and effect of radiotherapy in patients with stage Ⅰ or Ⅱ diffuse large B-cell lymphoma:a surveillance,epidemiology,and end results analysis[J].Int J Radiat Oncol Biol Phys,2008,72(5):1465-1471.DOI:10.1016/j.ijrobp.2008.02.068.
2015, Vol. 24 
